The National Healthcare Security Administration has introduced a pilot system allowing preparation of medical service pricing items to begin during the development of advanced technologies and products. The mechanism brings pricing considerations into the clinical research and innovative medical device review stages, supporting a more coordinated transition towards clinical application.
Applications are initiated by tertiary hospitals and assessed within a framework centred on clinical necessity and economic value. Expected-price commitments can support applications where economic evidence remains insufficient, while conditional pathways incorporate real-world value evaluation to inform subsequent pricing decisions.
For healthcare innovators, the pilot makes early collaboration with hospital partners and coordinated evidence generation increasingly important. Integrating clinical development, economic assessment and post-market data collection can help companies prepare the service-charging pathway alongside regulatory development and support the commercial introduction of new technologies.